WO2004050710A3 - Aldonsäure-ester, verfahren zu ihrer herstellung und verfahren zur herstellung von mit polysacchariden oder polysaccharid-derivaten an freien aminogruppen gekoppelten pharmazeutischen wirkstoffen - Google Patents

Aldonsäure-ester, verfahren zu ihrer herstellung und verfahren zur herstellung von mit polysacchariden oder polysaccharid-derivaten an freien aminogruppen gekoppelten pharmazeutischen wirkstoffen Download PDF

Info

Publication number
WO2004050710A3
WO2004050710A3 PCT/EP2003/013622 EP0313622W WO2004050710A3 WO 2004050710 A3 WO2004050710 A3 WO 2004050710A3 EP 0313622 W EP0313622 W EP 0313622W WO 2004050710 A3 WO2004050710 A3 WO 2004050710A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
producing
acid esters
active ingredients
aldonic acid
Prior art date
Application number
PCT/EP2003/013622
Other languages
English (en)
French (fr)
Other versions
WO2004050710A2 (de
Inventor
Klaus Sommermeyer
Original Assignee
Supramol Parenteral Colloids
Klaus Sommermeyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supramol Parenteral Colloids, Klaus Sommermeyer filed Critical Supramol Parenteral Colloids
Priority to KR1020057009533A priority Critical patent/KR101170033B1/ko
Priority to CA002504799A priority patent/CA2504799A1/en
Priority to AU2003288218A priority patent/AU2003288218B2/en
Priority to US10/537,176 priority patent/US20060052342A1/en
Priority to JP2004556278A priority patent/JP4749720B2/ja
Priority to EP03780109A priority patent/EP1567558A2/de
Priority to BR0316493-4A priority patent/BR0316493A/pt
Priority to MXPA05005572A priority patent/MXPA05005572A/es
Publication of WO2004050710A2 publication Critical patent/WO2004050710A2/de
Publication of WO2004050710A3 publication Critical patent/WO2004050710A3/de
Priority to NO20053179A priority patent/NO20053179L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/02—Esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/16—Ether-esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/18—Oxidised starch
    • C08B31/185—Derivatives of oxidised starch, e.g. crosslinked oxidised starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B33/00—Preparation of derivatives of amylose
    • C08B33/02—Esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B35/00—Preparation of derivatives of amylopectin
    • C08B35/02—Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die vorliegende Erfindung betrifft Aldonsäure-Ester von selektiv am reduzierenden Kettenende zu Aldonsäuren oxidierten Stärkefraktionen oder Stärkefraktions-Derivaten, Feststoff und Lösungen, die diese Aldonsäure-Ester enthalten. Des weiteren beschreibt die vorliegende Erfindung Verfahren zur Herstellung dieser Aldonsäure-Ester, Verfahren zur Herstellung von mit Polysacchariden oder Polysaccharid-Derivaten an freien Aminofunktionen gekoppelten pharmazeutischen Wirkstoffen sowie hierdurch erhärltliche pharmazeutische Wirkstoffe.
PCT/EP2003/013622 2002-12-04 2003-12-03 Aldonsäure-ester, verfahren zu ihrer herstellung und verfahren zur herstellung von mit polysacchariden oder polysaccharid-derivaten an freien aminogruppen gekoppelten pharmazeutischen wirkstoffen WO2004050710A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020057009533A KR101170033B1 (ko) 2002-12-04 2003-12-03 알돈산 에스테르, 알돈산 에스테르를 포함하는 고형물과 용액, 알돈산 에스테르를 제조하는 방법, 약제 활성 성분 및 약제 활성 성분 제조 방법
CA002504799A CA2504799A1 (en) 2002-12-04 2003-12-03 Aldonic acid esters, methods for producing the same, and methods for producing pharmaceutical active ingredients coupled to polysaccharides or polysaccharide derivatives on free amino groups
AU2003288218A AU2003288218B2 (en) 2002-12-04 2003-12-03 Aldonic acid esters, methods for producing the same, and methods for producing pharmaceutical active ingredients coupled to polysaccharides or polysaccharide derivatives on free amino groups
US10/537,176 US20060052342A1 (en) 2002-12-04 2003-12-03 Aldonic acid esters, methods for producing the same, and methods for producing pharmaceutical active ingredients coupled to polysaccharides or polysaccharide derivatives on free amino groups
JP2004556278A JP4749720B2 (ja) 2002-12-04 2003-12-03 アルドン酸エステル、その製造法、ならびに遊離アミノ基において多糖類または多糖誘導体と結合した医薬有効成分を製造するための方法
EP03780109A EP1567558A2 (de) 2002-12-04 2003-12-03 Aldonsäure-ester, verfahren zu ihrer herstellung und verfahren zur herstellung von mit polysacchariden oder polysaccharid-derivaten an freien aminogruppen gekoppelten pharmazeutischen wirkstoffen
BR0316493-4A BR0316493A (pt) 2002-12-04 2003-12-03 ésteres de ácido aldÈnico, métodos para produzir os mesmos, e métodos para produzir ingredientes ativos farmacêuticos ligados a polissacarìdicos ou derivados polissacarìdeos sobre grupos amino livres
MXPA05005572A MXPA05005572A (es) 2002-12-04 2003-12-03 Esteres de acido aldonico, metodos para producir el mismo y metodos para producir ingredientes activos farmaceuticos acoplados a polisacaridos o derivados de polisacaridos en grupos de aminos libres.
NO20053179A NO20053179L (no) 2002-12-04 2005-06-28 Aldonsyreestere, fremgangsmater for fremstilling derav og fremgangsmater for fremstilling av farmasoytisk aktive ingredienser som er bundet til polysakkarider eller polysakkarid-derivater pa frie aminogrupper.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10256558.9 2002-12-04
DE10256558A DE10256558A1 (de) 2002-12-04 2002-12-04 Ester von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe

Publications (2)

Publication Number Publication Date
WO2004050710A2 WO2004050710A2 (de) 2004-06-17
WO2004050710A3 true WO2004050710A3 (de) 2004-09-02

Family

ID=32403695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/013622 WO2004050710A2 (de) 2002-12-04 2003-12-03 Aldonsäure-ester, verfahren zu ihrer herstellung und verfahren zur herstellung von mit polysacchariden oder polysaccharid-derivaten an freien aminogruppen gekoppelten pharmazeutischen wirkstoffen

Country Status (15)

Country Link
US (1) US20060052342A1 (de)
EP (1) EP1567558A2 (de)
JP (1) JP4749720B2 (de)
KR (1) KR101170033B1 (de)
CN (1) CN100535015C (de)
AU (1) AU2003288218B2 (de)
BR (1) BR0316493A (de)
CA (1) CA2504799A1 (de)
DE (1) DE10256558A1 (de)
MX (1) MXPA05005572A (de)
NO (1) NO20053179L (de)
PL (1) PL210453B1 (de)
RU (1) RU2330046C2 (de)
WO (1) WO2004050710A2 (de)
ZA (1) ZA200503135B (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
JP2006516534A (ja) 2002-09-11 2006-07-06 フレセニウス・カビ・ドイッチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｈａｓ化ポリペプチド、特にｈａｓ化エリスロポエチン
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US20090281296A1 (en) * 2004-02-09 2009-11-12 Supramol Parenteral Colloid Gmbh Process for the production of conjugates from polysaccharides and polynucelotides
DE102004009783A1 (de) * 2004-02-28 2005-09-15 Supramol Parenteral Colloids Gmbh Hyperverzweigte Stärkefraktion, Verfahren zu ihrer Herstellung und ihre Konjugate mit pharmazeutischen Wirkstoffen
EP2336192A1 (de) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärke-Protein-Konjugate, durch reduktive Aminierung hergestellt.
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
EP2070951A1 (de) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Verfahren zur Herstellung eines Hydroxyalkylstärkederivats mit zwei Linkern
BRPI0913007A2 (pt) 2008-05-02 2019-09-24 Novartis Ag moléculas de ligação aprimoradas à base de fibronectina e usos das mesmas
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
WO2013113503A1 (en) 2012-01-31 2013-08-08 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and an oligonucleotide

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125492A (en) * 1974-05-31 1978-11-14 Pedro Cuatrecasas Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglioside-containing soluble polymers
DE3029307A1 (de) * 1980-08-01 1982-03-04 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Haemoglobin enthaltendes blutersatzmittel
EP0418523A1 (de) * 1989-08-25 1991-03-27 Chisso Corporation Amylose-Lysozym-Hybrid, ein Aktivzucker und Verfahren zur Herstellung
DE19628705A1 (de) * 1996-07-08 1998-01-15 Fresenius Ag Neue Sauerstoff-Transport-Mittel, diese enthaltende Hämoglobin-Hydroxyethylstärke-Konjugate, Verfahren zu deren Herstellung, sowie deren Verwendung als Blutersatzstoffe
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
WO2003000738A2 (de) * 2001-06-21 2003-01-03 Fresenius Kabi Deutschland Gmbh Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugats

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868781A (en) * 1956-04-23 1959-01-13 Monsanto Chemicals Carbohydrate esters of carboxylic acids and methods of preparing same
EP0019403B1 (de) * 1979-05-10 1985-07-31 American Hospital Supply Corporation Arzneimittelträger auf der Basis von Hydroxyalkyl-Stärke
DE3836600A1 (de) * 1988-10-27 1990-05-03 Wolff Walsrode Ag Kohlensaeureester von polysacchariden und verfahren zu ihrer herstellung
DE4130807A1 (de) * 1991-09-17 1993-03-18 Wolff Walsrode Ag Verfahren zur herstellung von polysaccharidcarbonaten
NZ250048A (en) * 1992-10-28 1994-10-26 Enzyme Bio Systems Ltd Production of maltodextrins by selective hydrolysation of starches by enzymatic methods
US5753468A (en) * 1996-08-05 1998-05-19 National Starch And Chemical Investment Holding Corporation Stable high viscosity starch based adhesive and method of preparation
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
IT1303738B1 (it) * 1998-11-11 2001-02-23 Aquisitio S P A Processo di reticolazione di polisaccaridi carbossilati.
AU1249001A (en) * 1999-06-11 2001-01-31 Nektar Therapeutics Al, Corporation Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers
JP4883515B2 (ja) * 1999-09-08 2012-02-22 ポリセリックス リミテッド 均一分子量ポリマー
CA2368501C (en) * 2000-02-28 2007-11-13 Grain Processing Corporation High purity maltose process and products
WO2003018639A1 (de) * 2001-08-22 2003-03-06 Supramol Parenteral Colloids Gmbh Hyperverzweigtes amylopektin zum einsatz in verfahren zur chirurgischen oder therapeutischen behandlung von säugern oder in diagnostizierverfahren, insbesondere zur verwendung als plasmavolumenexpander
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
FR2840612B1 (fr) * 2002-06-06 2005-05-06 Roquette Freres Polymeres solubles de glucose hautement branches et leur procede d'obtention
US7274854B2 (en) * 2002-06-27 2007-09-25 Pirelli & C. S.P.A. Polyimide optical waveguides and method for the preparation thereof
JP2006516534A (ja) * 2002-09-11 2006-07-06 フレセニウス・カビ・ドイッチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｈａｓ化ポリペプチド、特にｈａｓ化エリスロポエチン
DE10302520A1 (de) * 2003-01-23 2004-08-05 Supramol Parenteral Colloids Gmbh Kohlensäurediester von Stärkefraktionen und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US20080274948A1 (en) * 2003-08-08 2008-11-06 Fresenius Kabi Deutschland Gmbh Conjugates of Hydroxyalkyl Starch and G-Csf
DE102004009783A1 (de) * 2004-02-28 2005-09-15 Supramol Parenteral Colloids Gmbh Hyperverzweigte Stärkefraktion, Verfahren zu ihrer Herstellung und ihre Konjugate mit pharmazeutischen Wirkstoffen
AR048918A1 (es) * 2004-03-11 2006-06-14 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxietilo y eritropoyetina

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125492A (en) * 1974-05-31 1978-11-14 Pedro Cuatrecasas Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglioside-containing soluble polymers
DE3029307A1 (de) * 1980-08-01 1982-03-04 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Haemoglobin enthaltendes blutersatzmittel
EP0418523A1 (de) * 1989-08-25 1991-03-27 Chisso Corporation Amylose-Lysozym-Hybrid, ein Aktivzucker und Verfahren zur Herstellung
DE19628705A1 (de) * 1996-07-08 1998-01-15 Fresenius Ag Neue Sauerstoff-Transport-Mittel, diese enthaltende Hämoglobin-Hydroxyethylstärke-Konjugate, Verfahren zu deren Herstellung, sowie deren Verwendung als Blutersatzstoffe
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
WO2003000738A2 (de) * 2001-06-21 2003-01-03 Fresenius Kabi Deutschland Gmbh Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugats

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein

Also Published As

Publication number Publication date
DE10256558A1 (de) 2004-09-16
NO20053179D0 (no) 2005-06-28
US20060052342A1 (en) 2006-03-09
KR101170033B1 (ko) 2012-08-01
EP1567558A2 (de) 2005-08-31
JP4749720B2 (ja) 2011-08-17
KR20050072832A (ko) 2005-07-12
AU2003288218A1 (en) 2004-06-23
PL375693A1 (en) 2005-12-12
PL210453B1 (pl) 2012-01-31
AU2003288218B2 (en) 2010-05-20
WO2004050710A2 (de) 2004-06-17
CN100535015C (zh) 2009-09-02
CA2504799A1 (en) 2004-06-17
NO20053179L (no) 2005-08-15
JP2006509849A (ja) 2006-03-23
ZA200503135B (en) 2006-07-26
RU2005120736A (ru) 2006-01-20
CN1720264A (zh) 2006-01-11
MXPA05005572A (es) 2005-11-23
BR0316493A (pt) 2005-10-11
RU2330046C2 (ru) 2008-07-27

Similar Documents

Publication Publication Date Title
WO2004050710A3 (de) Aldonsäure-ester, verfahren zu ihrer herstellung und verfahren zur herstellung von mit polysacchariden oder polysaccharid-derivaten an freien aminogruppen gekoppelten pharmazeutischen wirkstoffen
WO2001064934A3 (en) High purity maltose process and products
WO2001044489A3 (de) Galactomannan-oligosaccharide und verfahren zu deren herstellung sowie deren verwendung
ATE215969T1 (de) Thermoplastisch verarbeitbare stärke bzw. stärkederivat-polymermischungen
WO2008012542A3 (en) Polysaccharide derivatives of erythropoietin
WO2003086291A3 (en) Urea compositions
WO2001040240A3 (en) Mono- and disaccharide derivatives
WO2007102149A3 (en) Hydrazido derivatives of hyaluronic acid
AU2003251221A1 (en) Microbeads of natural polysaccharide and hyaluronic acid and processes for preparing the same
CA2567582A1 (en) Anti-hypertensive dietary supplement derived from salmo or oncorhynchus protein hydrolysates
ATE284901T1 (de) Veresterte polysaccharidprodukte, beta-lacton ringgeöffnete ketendimer-produkte enthaltende zusammensetzungen und verfahren zur deren herstellung
WO2003059875A3 (en) DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION
MXPA03007303A (es) Productos de almidon hidrofobicamente esterificados y proceso para realizar los mismos.
WO2003008457A3 (en) Polysaccharidic esters of retinoic acid
HUP0300240A2 (hu) Polikarbonáttartalmú készítmények
WO2002085921A3 (de) Einfaches verfahren zur synthese von boswelliasäuren und derivaten davon
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2003005698A3 (en) Distal anastomosis system
WO2003049696A3 (en) Glucosamine organic acid adducts
PL360411A1 (en) Process for the production of chemically or enzymatically modified polysaccharides, and products made thereby
AU4709997A (en) Preparation of chemically reactive polysaccharides
WO2002070537A3 (en) Fusidic acid derivatives
WO2005027887A3 (en) Methods and compositions for improving endothelial function
WO2006094826A3 (en) Method for coupling enzymatically activated glycoconjugates to a hydroxyalkyl starch
AU2001268461A1 (en) Uncoupling proteins as targets for the treatment of heart failure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003780109

Country of ref document: EP

Ref document number: 2005/03135

Country of ref document: ZA

Ref document number: 168128

Country of ref document: IL

Ref document number: 2003288218

Country of ref document: AU

Ref document number: 200503135

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1727/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2504799

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/A/2005/005572

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057009533

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038A4701X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 375693

Country of ref document: PL

Ref document number: 2004556278

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2005120736

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020057009533

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003780109

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006052342

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10537176

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0316493

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10537176

Country of ref document: US